You are a senior compliance officer at a medical device company. The Director of Compliance has requested that you review the following 3 articles: (1) Innovation, Risk and Patient Empowerment/FDA Mandated Withdrawal of 23andMe Innovation, Risk and Patient Empowerment/FDA Mandated Withdrawal of 23andMe - Alternative Formats

(2) FDA versus Personal Genetic Testing FDA versus Personal Genetic Testing - Alternative Formats (3) 23andMe returns with modified, FDA-approved genetic tests summarizing the FDA's activities concerning 23andMe. In the Alert, you should include at least three direct quotes, two paraphrased passages, and one overall summary of each article.